New Drug Application Filed for Pixantrone

September 11, 2009

Cell Therapeutics, Inc, announced that the US Food and Drug Administration (FDA) has accepted and has filed for review the company’s New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). As we went to press, a Prescription Drug User Fee Act (PDUFA) date was to be established by the FDA regarding the review of the pixantrone NDA by September 4, 2009.

Cell Therapeutics, Inc, announced that the US Food and Drug Administration (FDA) has accepted and has filed for review the company’s New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin lymphoma (NHL). As we went to press, a Prescription Drug User Fee Act (PDUFA) date was to be established by the FDA regarding the review of the pixantrone NDA by September 4, 2009.